PHARMACEUTICAL MICROBIOLOGY

Why Regulators Focus on Burkholderia cepacia Complex Identification in Pharmaceuticals Why Regulators Focus on Burkholderia cepacia Complex Identification in Pharmaceuticals In pharmaceutical microbiology, very few microorganisms attract the same level of regulatory attention as Burkholderia cepacia complex (BCC) . Regulators do not focus on BCC because it is frequently detected, but because when it is missed, the consequences can directly impact patient safety. Repeated global product recalls, severe patient infections, and failures of traditional control strategies have established BCC as a high-risk, high-impact organism , particularly in non-sterile pharmaceutical products. Table of Contents Introduction Scientific Rationale Behind Regulatory Focus Regulatory Expectations and References Principle of BCC Identification Procedure Overview Identification Logic & Process Flow Risk-Based Failure Probability Practical Laboratory Scenarios Common...

USP , & Microbial Limit Testing – Complete Guide for Pharmaceuticals , & Microbial Limit Tests — detailed guide on methods, sample prep, microbial enumeration, pathogen detection, and compliance for pharmaceuticals and cosmetics."> , USP , USP , microbial limit test, microbial enumeration, specified microorganisms, pharmaceutical microbiology, contamination control, BCC detection"> Microbial contamination control is a cornerstone of pharmaceutical quality assurance. Non-sterile products must be tested for microbial load to ensure safety and compliance with pharmacopeial standards. The United States Pharmacopeia (USP) provides three critical chapters that guide microbial limit testing: <60> , <61> , and <62> . This guide dives deep into their purpose, methodology, media selection, sample preparation, interpretation, and compliance requirements. Understanding Microbial Limit Testing (MLT) Microbial Limit Testing (MLT) refers to the qua...